Literature DB >> 18617779

The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease.

Jean-Marc Sabate1, Nejma Ameziane, Jérôme Lamoril, Pauline Jouet, Jean-Pierre Farmachidi, Jean-Claude Soulé, Florence Harnois, Iradj Sobhani, Raymond Jian, Jean-Charles Deybach, Dominique de Prost, Benoit Coffin.   

Abstract

OBJECTIVES: CX3CR1, the receptor of CX3CL1/fractalkine, is involved in regulation of inflammatory response and the CX3CR1-I249-M280 naturally occurring mutants are associated with altered binding to the ligand. Our aim was to evaluate the frequency of CX3CR1 V249I and T280M polymorphisms and NOD2/CARD15 mutations in Crohn's disease patients and to search for a relationship with phenotype.
METHODS: Clinical data were retrospectively collected. V249I and T280M polymorphisms of CX3CR1 gene and NOD2/CARD15 mutations (R702W, G908R, 3020InsC) were identified.
RESULTS: Two hundred and thirty-nine patients (140 females, 39.7+/-14.1 years) were included. About 37.4% were heterozygous and 8.8% were homozygous for the V249I CX3CR1 polymorphism, 18.1% were heterozygous and 1.3% homozygous for the T280M CX3CR1 polymorphism and 35.9% had at least one of the three mutations of NOD2/CARD15. The T280M CX3CR1 polymorphism was not associated with any phenotype. In univariate analysis, stenosis was significantly associated with both V249I CX3CR1 polymorphism and 3020InsC NOD2/CARD15 mutations. In smoker patients carrying the CX3CR1 allele I249, there was a significant increase in the frequency of fibrostenosing disease [P=0.005, odds ratio (OR): 3.25] whereas this relationship disappeared in the group of nonsmokers (P=0.72). In multivariate analysis, 3020InsC NOD2/CARD15 mutations and the V249I CX3CR1 polymorphism were independent risk factors for intestinal stenosis (P=0.046, OR: 1.8 and P=0.044, OR: 2.4, respectively).
CONCLUSION: In Crohn's disease, V249I CX3CR1 polymorphism is associated with intestinal strictures, particularly in smokers. This association is independent of CARD15 mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617779     DOI: 10.1097/MEG.0b013e3282f824c9

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  17 in total

1.  Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis.

Authors:  Hale Gokcan; Erkan Yurtcu; Haldun Selcuk; Feride I Sahin
Journal:  Bosn J Basic Med Sci       Date:  2015-05-25       Impact factor: 3.363

Review 2.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 3.  Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease.

Authors:  Paolo Giuffrida; Massimo Pinzani; Gino R Corazza; Antonio Di Sabatino
Journal:  United European Gastroenterol J       Date:  2016-03-21       Impact factor: 4.623

Review 4.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

Review 5.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

6.  Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation.

Authors:  Jenny A Garcia; Paula A Pino; Makiko Mizutani; Sandra M Cardona; Israel F Charo; Richard M Ransohoff; Thomas G Forsthuber; Astrid E Cardona
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

7.  Fractalkine receptor polymorphism and chronic tonsillitis.

Authors:  Seda Turkoglu Babakurban; Selim S Erbek; Yunus Kasim Terzi; Fatih Arslan; Feride I Sahin
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-05       Impact factor: 2.503

8.  Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.

Authors:  Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder
Journal:  Clin Gastroenterol Hepatol       Date:  2021-06-02       Impact factor: 11.382

Review 9.  Genetic architecture of human fibrotic diseases: disease risk and disease progression.

Authors:  Agnès Gardet; Timothy S Zheng; Joanne L Viney
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

10.  Search for an association between V249I and T280M CX3CR1 genetic polymorphisms, endothelial injury and preeclampsia: the ECLAXIR study.

Authors:  Alain Stepanian; Soraya Benchenni; Tiphaine Beillat-Lucas; Sophie Omnes; Fannie Defay; Edith Peynaud-Debayle; Gabriel Baron; Agnès Le Querrec; Michel Dreyfus; Laurence Salomon; Vassilis Tsatsaris; Dominique de Prost; Laurent Mandelbrot
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.